TEG 5000

The presence of circulating giant platelets - often identified as functional megakaryocytes - can invalidate automated platelet counts and lead to unnecessary transfusions. This study suggests that thromboelastography (TEG) provides a more accurate assessment of actual hemostatic function in these cases. Consequently, TEG serves as a critical diagnostic tool to guide transfusion management and avoid redundant treatments in critically ill patients.

"In summary, modified VET assays show promise as rapid point-of-care tools for DOAC detection in emergency settings. Ecarin-based tests appear reliable for dabigatran, while Russell's Viper Venom and low-tissue-factor approaches may enable detection of direct factor Xa inhibitors. However, further clinical validation and standardization are required before routine implementation."

"Reference values for the Northern region of Mexico have been calculated and are characterized by a shorter clot reaction time, faster clot dynamics, higher angle values, overall greater curve amplitude, and no differences in enzymatic lysis activity compared to samples from other geographic regions."

"Our data indicate significant value of the model for early detection of patients with high risk of SAP. Integration of biomarkers, hemostasis parameters and clinical assessments significantly increases the accuracy of risk stratification. This can contribute to optimized treatment and reduction of complications."

"In conclusion, TEG parameters displayed no significant alterations between exacerbation and follow-up. The nuanced variance in APTT hints at the intricate influence of exacerbation on coagulation dynamics, urging further exploration."

Viscoelastic testing (VET) has revolutionized modern coagulation management by offering rapid, real-time insights into the entire hemostatic process. By enabling precise, data-driven transfusion algorithms at the point of care, VET-guided strategies significantly improve patient blood management and clinical outcomes in high-stakes environments like trauma and cardiac surgery.

"The thromboelastograph (TEG) has undergone several modifications, but the concept on which the original TEG was based (cup and pin technology) remained up to the TEG 5000 analyzer (Haemonetics, Braintree, MA). In a previous chapter, we reviewed the advantages and limitations of TEG 5000 as well as factors that affect TEG and which must be considered when interpreting tracings. In the present chapter, we provide a description of the TEG 5000 principle and its operation protocol."

The study concludes that the TEG 6s and TEG 5000 are not interchangeable for canine patients. Despite using the same reagents, they showed poor overall agreement due to different measurement technologies (resonance-frequency vs. cup-and-pin). Agreement was only satisfactory for Maximum Amplitude (MA) in specific assays, and the Functional Fibrinogen test proved unsuitable for dogs. While the TEG 6s is more portable and automated, clinicians must use device-specific reference intervals rather than TEG 5000 data.

"VETs assess dynamic aspects of hemostasis, regarding both clot formation and dissolution so allowing to evaluate a “dynamic” modification of hemostasis over time. They could provide to clinicians more information about the CAC, identifying at the patient bedside the presence of a hypercoagulable state and hypofibrinolysis, that are more evident than in coagulopathy during the sepsis. In regard to VTE prediction, the results of VETs analysis demonstrate a hypercoagulable state that is not predictive for thrombotic events in critically ill COVID-19 patients. The clinical application of VETs in patients with severe COVID-19 infection should be combined with biohumoral parameters (i.e. D-dimer). Future studies on large patient populations should define the usefulness of VETs as prognostic markers of micro- and macrothrombosis in severe COVID-19 patients to improve morbidity and mortality. The dynamic coagulative approach based on the use of VETs, associated to laboratory tests, might help to guide a personalized anticoagulant strategy, well knowing that “one size does not fit all”."

"This systematic review and analysis indicate that TEG‐guided hemostatic therapy can enhance blood product management and improve key patient outcomes, including LoS, bleeding rate, and mortality."

"Both TEG 5000-FLEV and TEG 6s-CFF correlated moderately with Clauss fibrinogen but decreased in correlation in both hyperfibrinogenemia and hypofibrinogenemia. Thus, we caution relying on TEG 5000 or TEG 6s to be the only laboratory measurement to guide fibrinogen replacement when resuscitating trauma patients at risk for TIC and TEG 5000-FLEV for assessing fibrinogen in patients with ESRD at risk for thrombotic events."

"Despite weaknesses in correlation and agreement both VET devices suggested appropriate coagulation management based on the simulated transfusion algorithms. Quantra and TEG-5000 are not interchangeable and none of them can be considered as "the gold standard"."

"Using citrated-recalcified blood to perform TEG might lead to underestimation of the effect of heparin."

This prospective study demonstrates that the TEG5000 and TEG6s systems show substantial diagnostic agreement when assessing hemostasis in pediatric cardiac surgery patients. While some variability was noted in reaction times, the devices displayed low bias and high consistency in measuring critical parameters like Maximum Amplitude (MAK) and K time (KK). These findings suggest that the two platforms are clinically interchangeable for monitoring clot strength and formation in this vulnerable population.

"CK LY30 above the ULN is a sensitive but not specific cutoff for hyperfibrinolysis. At least moderately elevated CK LY30 carries more clinical portent on the TEG 6s instrument than on the TEG 5000. These TEG instruments are not sensitive to low concentrations of tPA."

Traditional coagulation tests (PT/APTT) often fail in the NICU because they do not account for developmental hemostasis—the unique, balanced clotting state of newborns. This often leads to unnecessary and potentially harmful blood transfusions. In contrast, Viscoelastic Coagulation Tests (VCTs) like TEG and ROTEM offer a rapid, bedside "global" view of clotting using minimal blood volumes. By providing real-time data, VCTs enable individualized, goal-directed therapy for critical conditions such as sepsis and ECMO, effectively optimizing blood product use and improving neonatal outcomes.

Modern cartridge-based VET - specifically the TEG 6s, HemoSonics Quantra, and ROTEM sigma - offers superior portability and ease of use compared to traditional laboratory methods. Despite limited randomized evidence for these new-generation devices, VET-guided algorithms effectively reduce blood product usage without compromising patient outcomes. Future validation of clinical cut-offs will be key to optimizing transfusion management.

"In conclusion, TEG®6S is a good alternative POC device that is comparable to the TEG®5000, and the results from both devices can be interchangeably used for clinical diagnostics. Low rewarming TEG®6S MA (<40 mm) is associated with increased risk for bleeding in pediatric patients undergoing high-risk cardiac surgery on CPB. Furthermore, a multicenter clinical validation of the TEG®6S platelet calculator would be necessary for designing a more accurate bleeding management algorithm in this patient population."

Viscoelastic Hemostatic Assays (VHAs) have transitioned from legacy "cup and pin" research tools to essential cartridge-based point-of-care devices. By providing a real-time, cell-based assessment of the entire clot lifespan—from initiation to lysis—systems like TEG, ROTEM, and Quantra allow for precise, goal-directed blood component therapy in surgery and trauma. While modern automation has improved reproducibility and bedside utility, limitations remain regarding the detection of von Willebrand disease and certain antiplatelet or anticoagulant effects. Despite these gaps, VHAs continue to be a cornerstone of personalized medicine in managing complex coagulopathies, including those associated with COVID-19.

Viscoelastic testing through TEG and ROTEM provides a rapid, real-time assessment of neonatal coagulation, bridging the gap left by conventional tests that often fail to account for the nuances of developmental hemostasis. By requiring minimal blood volumes, these tools allow for precise, goal-oriented transfusion strategies and early detection of complications in cases of sepsis or cardiac surgery. While they offer a superior look at the dynamic process of clot formation in newborns, the establishment of standardized reference ranges remains essential for their full integration into routine clinical practice.

"Strong correlations were observed between quantra parameters FCS and PCS with Clauss Fibrinogen and Platelet count. While Performance from ROC curves for predicted thrombocytopenia <150k platelet/µL is similar with TEG-5000, they are better for predicted fibrinogen concentration and prolonged aPTT."

"Current diagnostic tests demonstrate moderate predictive accuracy for excessive bleeding following cardiac surgery. Additional biomarkers of multimorbidity, organ dysfunction, and biological aging did not improve discrimination or clinical utility substantially. Revised definitions of excessive bleeding phenotypes based on these results should reduce barriers to the understanding of underlying disease processes."